Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R306465 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| R306465 | DRUG | - |
Inclusion Criteria: * Confirmed solid malignancy that is metastatic or unresectable, and for which standard curative or palliative measures does not exist or are no longer effective * Performance status (based on the Eastern Cooperative Oncology Group assessments) of \<= 2 * Life expectancy \> 3 mo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
R306465 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be cancerous. It was evaluated in patients with advanced solid malignancies to assess its safety and how the body absorbs, breaks down, and eliminates the drug.
R306465 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is an investigational small molecule in the oncology therapeutic area, studied for its potential use in treating neoplasms.
R306465 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and pharmacological properties in patients with advanced solid malignancies.
R306465 has one completed clinical trial registered as NCT00677001. This Phase 1 study evaluated the safety of R306465 and studied its absorption, breakdown, and elimination in 15 patients with advanced solid malignancies. The trial was uncontrolled and not randomized or double-blinded.
No alternative names for R306465 have been identified. The drug is known by its code name R306465 and is being developed by Johnson & Johnson as an investigational small molecule for the treatment of neoplasms.